Locations:
Search IconSearch
December 29, 2021/Cancer/Patient Support

Managing Intractable Nausea and Vomiting in the Palliative Care Setting

Identifying the underlying cause key to successful treatment

Nausea

A recent article published in American Academy of Hospice and Palliative Medicine provides an overview of approaches for treating intractable nausea and vomiting in the palliative care setting. Published by Cleveland Clinic palliative medicine specialist Kyle Neale, DO, the article explains that nausea and vomiting are best addressed using a mechanistic approach focused on uncovering the underlying cause of the patient’s symptoms.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Addressing multifactorial causes

There are multiple culprits for nausea and vomiting, particularly in the palliative care and oncology populations, including chemotherapy, anxiety, constipation, delayed motility of the gastrointestinal tract and functional bowel disorder. Although a number of medications can be trialed to alleviate the patient’s symptoms, Dr. Neale says there is no one-size-fits-all approach. The key, he explains, is to properly diagnose and treat the underlying cause by incorporating medications of different classes when needed.

“For chemotherapy-related nausea and vomiting, we usually prescribe ondansetron or prochlorperazine; we may occasionally escalate to a longer-acting drug like olanzapine,” explains Dr. Neale, a staff physician in Taussig Cancer Institute. For patients with anticipatory anxiety, drugs like lorazepam can be used to manage panic or anxiety episodes. Metoclopramide can also be helpful for encouraging motility and mitigating nausea.”

Many of the drugs clinicians have historically used to treat nausea and vomiting were originally designed for other purposes, he adds.

“For example, metoclopramide was initially derived to encourage motility in patients with poorly controlled diabetes, but it’s actually a very effective nausea drug as well. Olanzapine is actually an antipsychotic; at lower doses, however, it can be highly effective for managing severe chemotherapy-induced nausea and vomiting.”

Dr. Neale emphasizes that when there are several reasons behind a patient’s symptoms, an appropriate therapeutic regimen should be prescribed based on each medication’s mechanism of action.

Advertisement

“We know that the neurotransmitters in the area of the brain that promote nausea and vomiting are affected by many common medicines, so potential overlap should be considered,” he says. “For example, olanzapine targets many different neurotransmitters – a nice benefit that enables us to cover a lot of bases when several different causes of nausea are suspected.”

Ensuring safe treatment

“In most cases, nausea and vomiting can be well-controlled with medication, so providing relatively rapid relief is simply a matter of finding the right treatment,” explains Dr. Neale. In general, nausea and vomiting are managed for as long as the underlying cause is present, but patients rarely require ongoing treatment.

Although available drugs for treating nausea and vomiting are quite safe, Dr. Neale cautions that care must be taken when adding medications to the patient’s existing drug regimen.

“We’re cautious when combining some of these drugs because of their potential to cause irreversible neurologic interactions in the long-term,” he says. “As a result, we judiciously avoid prescribing treatments that trigger too much of a dopamine or serotonin response. We also have to be careful that a patient’s other medications – particularly antidepressants and other antiemetics – are not activating too many of those neurotransmitters.”

Patients who are interested in incorporating complementary therapies such as meditation, acupuncture and aromatherapy are encouraged to explore options available through the Cleveland Clinic Center for Functional Medicine.

Advertisement

Finally, Dr. Neale encourages patients to speak up if their nausea and vomiting persists. “If the first medication does not work, other options are available,” he says.

Advertisement

Related Articles

Physician checking patient's heart rate
July 15, 2026/Cancer

First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events

Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.

Thyroid cancer illustration
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Ad